Alexiev Ivailo, Shankar Anupama, Wensing A M J, Beshkov Danail, Elenkov Ivaylo, Stoycheva Mariyana, Nikolova Daniela, Nikolova Maria, Switzer William M
National Reference Laboratory of HIV, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria
Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA, USA.
J Antimicrob Chemother. 2015;70(6):1874-80. doi: 10.1093/jac/dkv011. Epub 2015 Feb 3.
To determine transmitted drug resistance (TDR) and HIV-1 genetic diversity in Bulgaria.
The prevalence of TDR and HIV-1 subtypes was determined in 305/1446 (21.1%) persons newly diagnosed with HIV/AIDS from 1988 to 2011. TDR mutations (TDRMs) in protease and reverse transcriptase were defined using the WHO HIV drug mutation list. Phylogenetic analysis was used to infer polymerase (pol) genotype.
TDRMs were found in 16/305 (5.2%) persons, 11 (3.6%) with resistance to NRTIs, 5 (1.6%) with resistance to NNRTIs and 3 (0.9%) with resistance to PIs. Dual-class TDRMs were found in three (1.0%) patients and one statistically supported cluster of TDRMs comprising two individuals with subtype B infection. TDRMs were found in 10 heterosexuals, 4 MSM and two intravenous drug users. Phylogenetic analyses identified high HIV-1 diversity consisting of mostly subtype B (44.6%), subtype C (3.3%), sub-subtype A1 (2.6%), sub-subtype F1 (2.3%), sub-subtype A-like (3.6%), subtype G (0.3%), CRF14_BG (1.6%), CRF05_DF (1.3%), CRF03_AB (0.3%) and unique recombinant forms (1.3%).
We found a low prevalence of TDR against a background of high HIV-1 genetic diversity among antiretroviral-naive patients in Bulgaria. Our results provide baseline data on TDR and support continued surveillance of high-risk populations in Bulgaria to better target treatment and prevention efforts.
确定保加利亚的传播性耐药(TDR)情况及HIV-1基因多样性。
对1988年至2011年新诊断出的305/1446例(21.1%)HIV/AIDS患者进行TDR及HIV-1亚型流行率测定。使用世界卫生组织HIV药物突变列表定义蛋白酶和逆转录酶中的TDR突变(TDRMs)。采用系统发育分析推断聚合酶(pol)基因型。
在16/305例(5.2%)患者中发现TDRMs,11例(3.6%)对核苷类逆转录酶抑制剂(NRTIs)耐药,5例(1.6%)对非核苷类逆转录酶抑制剂(NNRTIs)耐药,3例(0.9%)对蛋白酶抑制剂(PIs)耐药。在3例(1.0%)患者中发现双类TDRMs,并且有一个统计学上支持的TDRMs聚类,包括两名B亚型感染个体。在10名异性恋者、4名男男性行为者和2名静脉吸毒者中发现了TDRMs。系统发育分析确定HIV-1具有高度多样性,主要包括B亚型(44.6%)、C亚型(3.3%)、A1亚亚型(2.6%)、F1亚亚型(2.3%)、A样亚亚型(3.6%)、G亚型(0.3%)、CRF14_BG(1.6%)、CRF05_DF(1.3%)、CRF03_AB(0.3%)和独特重组形式(1.3%)。
我们发现在保加利亚未接受抗逆转录病毒治疗的患者中,在HIV-1基因高度多样性的背景下,TDR的流行率较低。我们的结果提供了关于TDR的基线数据,并支持继续对保加利亚的高危人群进行监测,以便更好地确定治疗和预防工作的目标。